Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure Biocytogen announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences,…
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control Agilent Technologies Inc. announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine,…
Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer Aphios Corporation announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a…
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific…
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, announced that it will present new preclinical data on TFG-001 at the 7th…
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO)…
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026 SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, announced that the company and key collaborators…
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis Baszucki Group announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic…
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as the first TROP2-directed antibody-drug conjugate for first-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for…
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Bristol Myers Squibb announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society…
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality…